1.Moore, PS. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clinical Infectious Diseases 1992; 14: 515–525.
2.Harrison, LH, Trotter, CL, Ramsay, ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27: B51–63.
3.Caugant, DA, Maiden, MC. Meningococcal carriage and disease – population biology and evolution. Vaccine 2009; 27: B64–70.
4.Peltola, H. Meningococcal disease: still with us. Reviews of Infectious Diseases 1983; 5: 71–91.
5.Maiden, MC, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proceedings of the National Academy of Sciences USA 1998; 95: 3140–3145.
6.Zhu, P, et al. Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proceedings of the National Academy of Sciences USA 2001; 98: 5234–5239.
7.Mayer, LW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. Journal of Infectious Diseases 2002; 185:1596–1605.
8.Shao, Z, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006; 367: 419–423.
9.Zhou, H, et al. Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008. Epidemiology and Infection 2012; 140: 1296–1303.
10.Smith, H. What happens to bacterial pathogens in vivo? Trends in Microbiology 1998; 6: 239–243.
11.Coureuil, M, et al. Meningococcal type IV pili recruit the polarity complex to cross the brain endothelium. Science 2009; 325: 83–87.
12.Virji, M, et al. Identification of epitopes recognized by monoclonal antibodies SM1 and SM2 which react with all pili of Neisseria gonorrhoeae but which differentiate between two structural classes of pili expressed by Neisseria meningitidis and the distribution of their encoding sequences in the genomes of Neisseria spp. Journal of General Microbiology 1989; 135: 3239–3251.
13.Virji, M, et al. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Molecular Microbiology 1991; 5: 1831–1841.
14.Greiner, LL, et al. Biofilm formation by Neisseria gonorrhoeae. Infection and Immunity 2005; 73: 1964–1970.
15.Seifert, HS, et al. Shuttle mutagenesis of Neisseria gonorrhoeae: pilin null mutations lower DNA transformation competence. Journal of Bacteriology 1990; 172: 40–46.
16.Comanducci, M, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. Journal of Experimental Medicine 2002; 195: 1445–1454.
17.Comanducci, M, et al. NadA diversity and carriage in Neisseria meningitidis. Infection and Immunity 2004; 72: 4217–4223.
18.Lucidarme, J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. Journal of Clinical Microbiology 2009; 47: 3577–3589.
19.Bambini, S, et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009; 27: 2794–2803.
20.Lucidarme, J, et al. Characterisation of fHbp, nhba (gna2132), nadA, porA and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clinical and Vaccine Immunology 2010; 17: 919–929.
21.Cehovin, A, et al. Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine 2010; 28: 4817–4826.
22.Rusniok, C, et al. NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biology 2009; 10: R110.
23.Parkhill, J, et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000; 404: 502–506.
24.Tettelin, H, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287: 1809–1815.
25.Bentley, SD, et al. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genetics 2007; 3: e23.
26.Schoen, C, et al. Whole-genome sequence of the transformable Neisseria meningitidis serogroup A strain WUE2594. Journal of Bacteriology 2011; 193: 2064–2065.
27.Wang, Q, Shao, Z, Wang, X. Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains. Infection and Immunity 2010; 78: 3883–3888.
28.Stuart, AH, John, KD. Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiology Reviews 2009; 33: 521–530.
29. . Chamot-Rooke, J, et al. Posttranslational modification of pili upon cell contact triggers N. meningitidis dissemination. Science 2011, 331: 778–782.
30.Zhang, X, et al. Genetic characteristics of serogroup A meningococci circulating in China, 1956–2005. Clinical Microbiology and Infection 2008; 14: 555–561.
31.Zhang, X, et al. Molecular characterization of serogroup C Neisseria meningitidis isolated in China. Journal of Medical Microbiology 2007; 56: 1224–1229.
32.Siegel, M, et al. Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro. Journal of Infectious Diseases 1982; 145: 300–310.
33.Tramont, EC, et al. Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. Journal of Clinical Investigation 1981; 68: 881–888.
34.Criss, AK, Kline, KA, Seifert, HS. The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae. Molecular Microbiology 2005; 58: 510–519.
35.Bai, X, et al. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opinion on Biological Therapy 2011; 11: 969–985.
36.Snape, MD, Pollard, AJ. Meningococcal polysaccharide–protein conjugate vaccines. Lancet Infectious Diseases 2005; 5: 21–30.
37.Lewis, S, et al. Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Review of Vaccines 2009; 8: 729–745.